CT Clinical Trials

5 recruiting

CT Trials at a Glance

11,018 actively recruiting trials for ct are listed on ClinicalTrialsFinder across 6 cities in 158 countries. The largest study group is Not Applicable with 4,183 trials, with the heaviest enrollment activity in Houston, New York, and Boston. Lead sponsors running ct studies include Mayo Clinic, M.D. Anderson Cancer Center, and National Cancer Institute (NCI).

Treatments under study

About CT Clinical Trials

Looking for clinical trials for CT? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new CT trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about CT clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 11,018 trials

Recruiting

Prospective Follow-up of the Prevision Hip Stem With Comparison of Different Implant Variants

Revision Total Hip ArthroplastyPeriprosthetic Fracture of Hip
Aesculap AG120 enrolled2 locationsNCT06626490
Recruiting
Phase 2

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell CarcinomaResectable Pancreatic CarcinomaResectable Pancreatic Adenocarcinoma+4 more
National Cancer Institute (NCI)152 enrolled453 locationsNCT04858334
Recruiting

Collection of Lung Fluid and Tissue Samples for Research

Respiratory Tract DiseasesBronchoscopyLeukocyte Disorders
National Heart, Lung, and Blood Institute (NHLBI)550 enrolled1 locationNCT00471250
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2Phase 3

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)189 enrolled244 locationsNCT05058651
Recruiting
Phase 2

18F-Fluciclovine PET/CT in Multiple Myeloma

Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI)60 enrolled1 locationNCT06103838
Recruiting

Data Collection Study of Pediatric and Adolescent Gynecology Conditions

Disorders of Sex Development (DSD)Pediatric and Adolescent Cancers of the Genital TractReproductive Endocrine Conditions in Puberty+1 more
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)11,000 enrolled1 locationNCT04717349
Recruiting

Host Response to Infection and Treatment in Filarial Diseases

HelminthiasisFilariasisParasitic Infection+2 more
National Institute of Allergy and Infectious Diseases (NIAID)500 enrolled1 locationNCT00001230
Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting

Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients

AnthraxBacillus Infections
National Institute of Allergy and Infectious Diseases (NIAID)200 enrolled1 locationNCT00050310
Recruiting
Phase 2

Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study

Weight GainHealthy VolunteerMetabolic Effects+1 more
National Institute of Allergy and Infectious Diseases (NIAID)120 enrolled1 locationNCT05652478
Recruiting
Not Applicable

Characterization of Nociception Phenotype in Individuals With Intellectual Disability

Intellectual Disability
National Institutes of Health Clinical Center (CC)215 enrolled1 locationNCT05473429
Recruiting
Phase 1

MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)

HIV Infection
Merck Sharp & Dohme LLC28 enrolled2 locationsNCT07042945
Recruiting
Phase 2

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)84 enrolled274 locationsNCT03739814
Recruiting

Diagnosis and Treatment of Leishmania Infections

LeishmaniasisSkin Diseases, ParasiticEuglenozoa Infections+1 more
National Institute of Allergy and Infectious Diseases (NIAID)289 enrolled1 locationNCT00344188
Recruiting
Phase 1

Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

Palliative CareIntractable Pain
National Institute of Dental and Craniofacial Research (NIDCR)45 enrolled1 locationNCT00804154
Recruiting

Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV

ImmunodeficienciesHIVInfectious Diseases
National Institute of Allergy and Infectious Diseases (NIAID)2,419 enrolled2 locationsNCT00001281
Recruiting

Modeling Host-Pathogen Interaction Using Lymphoid Organoids

Staphylococcal Infections
National Institute of Allergy and Infectious Diseases (NIAID)500 enrolled2 locationsNCT06479837
Recruiting

Development of a Wearable Point of Care Monitoring Device for Pediatric Obstructive Sleep Apnea

Pediatric Obstructive Sleep Apnea
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)120 enrolled1 locationNCT05052216
Recruiting

Distinguishing Tics and Functional Tics Using Clinical Neurophysiological Techniques

TicsFunctional Tics
National Institute of Neurological Disorders and Stroke (NINDS)75 enrolled1 locationNCT07137442